Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma

od Owen, Dwight, Chu, Benjamin, Lehman, Amy M., Annamalai, Lakshmanan, Yearley, Jennifer H., Shilo, Konstantin, Otterson, Gregory A.
Izdano u J Thorac Oncol (2018)

Evaluating the Efficacy of Lay Health Advisors for Increasing Risk-appropriate Pap Test Screening: A randomized controlled trial among Ohio Appalachian women

od Paskett, Electra D., McLaughlin, John M., Lehman, Amy M., Katz, Mira L., Tatum, Cathy M., Oliveri, Jill M.
Izdano 2011

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

od Yeh, Yuh-Ying, Ozer, Hatice Gulcin, Lehman, Amy M., Maddocks, Kami, Yu, Lianbo, Johnson, Amy J., Byrd, John C.
Izdano u Blood (2015)

MIF Antagonist (CPSI-1306) Protects against UVB-Induced Squamous Cell Carcinoma

od Nagarajan, Priyadharsini, Tober, Kathleen L., Riggenbach, Judith A., Kusewitt, Donna F., Lehman, Amy M., Sielecki, Thais, Pruitt, James, Satoskar, Abhay R., Oberyszyn, Tatiana M.
Izdano u Mol Cancer Res (2014)

Debating Deposits: An inter-observer variability study of lymph nodes and pericolonic tumor deposits in colonic adenocarcinoma

od Rock, Jonathan B., Washington, Mary Kay, Adsay, Volkan, Greenson, Joel K., Montgomery, Elizabeth A., Robert, Marie E., Yantiss, Rhonda K., Lehman, Amy M., Frankel, Wendy L.
Izdano 2013

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia

od Yeh, Yuh-Ying, Chen, Rong, Hessler, Joshua, Mahoney, Emilia, Lehman, Amy M., Heerema, Nyla A., Grever, Michael R., Plunkett, William, Byrd, John C., Johnson, Amy J.
Izdano u Oncotarget (2014)

Psychosocial Predictors of Adherence to Risk-appropriate Cervical Cancer Screening Guidelines: a cross sectional study of women in Ohio Appalachia participating in the Community Aw...

od Paskett, Electra D., McLaughlin, John M., Reiter, Paul L., Lehman, Amy M., Rhoda, Dale A., Katz, Mira L., Hade, Erinn M., Post, Douglas M., Ruffin, Mack T.
Izdano 2009

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

od Hing, Zachary A., Mantel, Rose, Beckwith, Kyle A., Guinn, Daphne, Williams, Erich, Smith, Lisa L., Williams, Katie, Johnson, Amy J., Lehman, Amy M., Byrd, John C., Woyach, Jennifer A., Lapalombella, Rosa
Izdano u Blood (2015)

NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

od Chen, Timothy L., Tran, Minh, Lakshmanan, Aparna, Harrington, Bonnie K., Gupta, Nikhil, Goettl, Virginia M., Lehman, Amy M., Trudeau, Stephen, Lucas, David M., Johnson, Amy J., Byrd, John C., Hertlein, Erin
Izdano u Blood (2017)

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

od Dong, Shuai, Harrington, Bonnie K., Hu, Eileen Y., Greene, Joseph T., Lehman, Amy M., Tran, Minh, Wasmuth, Ronni L., Long, Meixiao, Muthusamy, Natarajan, Brown, Jennifer R., Johnson, Amy J., Byrd, John C.
Izdano u J Clin Invest (2018)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

od Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Izdano u J Hematol Oncol (2021)

Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer

od Lustberg, Maryam B., Povoski, Stephen P., Zhao, Weiqiang, Ziegler, Rebecca M., Sugimoto, Yasuro, Ruppert, Amy S., Lehman, Amy M., Shiels, Donna R., Mrozek, Ewa, Ramaswamy, Bhuvaneswari, Layman, Rachel M., Brueggemeier, Robert W., Shapiro, Charles L.
Izdano 2011

Ibrutinib treatment improves T cell number and function in CLL patients

od Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.
Izdano u J Clin Invest (2017)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies

od Hing, Zachary A., Fung, Ho Yee Joyce, Ranganathan, Parvathi, Mitchell, Shaneice, El-Gamal, Dalia, Woyach, Jennifer A., Williams, Katie, Goettl, Virginia M., Smith, Jordan, Yu, Xueyan, Meng, Xiaomei, Sun, Qingxiang, Cagatay, Tolga, Lehman, Amy M., Lucas, David M., Baloglu, Erkan, Shacham, Sharon, Kauffman, Michael G., Byrd, John C., Chook, Yuh Min, Garzon, Ramiro, Lapalombella, Rosa
Izdano u Leukemia (2016)

The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation

od Reiff, Sean D., Mantel, Rose, Smith, Lisa L., Greene, JT, Muhowski, Elizabeth M., Fabian, Catherine A., Goettl, Virginia M., Tran, Minh, Harrington, Bonnie K., Rogers, Kerry A., Awan, Farrukh T., Maddocks, Kami, Andritsos, Leslie, Lehman, Amy M., Sampath, Deepa, Lapalombella, Rosa, Eathiraj, Sudharshan, Abbadessa, Giovanni, Schwartz, Brian, Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
Izdano u Cancer Discov (2018)

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

od Dubovsky, Jason A., Beckwith, Kyle A., Natarajan, Gayathri, Woyach, Jennifer A., Jaglowski, Samantha, Zhong, Yiming, Hessler, Joshua D., Liu, Ta-Ming, Chang, Betty Y., Larkin, Karilyn M., Stefanovski, Matthew R., Chappell, Danielle L., Frissora, Frank W., Smith, Lisa L., Smucker, Kelly A., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami, Lehman, Amy M., Furman, Richard, Sharman, Jeff, Mishra, Anjali, Caligiuri, Michael A., Satoskar, Abhay R., Buggy, Joseph J., Muthusamy, Natarajan, Johnson, Amy J., Byrd, John C.
Izdano 2013

BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor

od Ozer, Hatice Gulcin, El-Gamal, Dalia, Powell, Ben, Hing, Zachary A., Blachly, James S., Harrington, Bonnie, Mitchell, Shaneice, Grieselhuber, Nicole R., Williams, Katie, Lai, Tzung-Huei, Alinari, Lapo, Baiocchi, Robert A., Brinton, Lindsey, Baskin, Elizabeth, Cannon, Matthew, Beaver, Larry, Goettl, Virginia M., Lucas, David M., Woyach, Jennifer A., Sampath, Deepa, Lehman, Amy M., Yu, Lianbo, Zhang, Jiazhong, Ma, Yan, Zhang, Ying, Spevak, Wayne, Shi, Songyuan, Severson, Paul, Shellooe, Rafe, Carias, Heidi, Tsang, Garson, Dong, Ken, Ewing, Todd, Marimuthu, Adhirai, Tantoy, Christina, Walters, Jason, Sanftner, Laura, Rezaei, Hamid, Nespi, Marika, Matusow, Bernice, Habets, Gaston, Ibrahim, Prabha, Zhang, Chao, Mathé, Ewy A, Bollag, Gideon, Byrd, John C., Lapalombella, Rosa
Izdano u Cancer Discov (2018)